Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group.
about
Vigabatrin versus carbamazepine monotherapy for epilepsyVigabatrin versus carbamazepine monotherapy for epilepsyA controlled study of vigabatrin and visual abnormalitiesCarbamazepine is not a substrate for P-glycoproteinThe promise of new antiepileptic drugs.ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.Adverse effects of antiepileptic drugs.Prevention of adult asthma by early intervention during childhood: potential value of new generation immunomodulatory drugs.New anti-epileptic drugs for the 21st century.Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations.Treating epilepsy across its different stages.Clinical pharmacology and therapeutic use of the new antiepileptic drugs.Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elementsWhat can we learn from clinical trials of anticonvulsant drugs in epilepsy?The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.Rash in psychiatric and nonpsychiatric adolescent patients receiving lamotrigine in Korea: a retrospective cohort study.Medications associated with weight gain.Optimizing epilepsy management in teenagers.Growth in Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency.Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy.Treatment of refractory complex partial seizures: role of vigabatrin.The use of recently approved antiepileptic drugs: use with caution, use in refractory patients or use as first-line indications?Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.Pharmacotherapy of focal epilepsy in children: a systematic review of approved agents.Cutaneous Adverse Effects of Neurologic Medications.Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach.Efficacy and Tolerability of Antiepileptic Drugs in Patients with Focal Epilepsy: Systematic Review and Network Meta-analyses.Response to Early AED Therapy and Its Prognostic Implications.Rash from antiepileptic drugs: influence by gender, age, and learning disability.Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy.Clinical trial response and dropout rates with olanzapine versus risperidone.The safety and effectiveness of newer antiepileptics: a comparative postmarketing cohort study.Randomized dose-controlled study of topiramate as first-line therapy in epilepsy.Intravenous carbamazepine: a new formulation of a familiar drug.Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of tCan Evidence-Based Guidelines and Clinical Trials Tell us How to Treat Patients?
P2860
Q24187744-2CC271EA-4DDD-4214-901B-041CA2DD317EQ24203845-4EF163DF-9A68-4E49-8288-235D96DDCCD6Q28344211-BB1BBD6F-F6F2-4D3E-938F-A1B26FCDDD9FQ28363548-94C939A7-16B3-40E8-993B-F3D4839F6ECCQ30674774-D8425BED-0640-45A9-A8F5-7ACFCDB16B79Q33252737-C706C161-F822-41F1-9F4B-87789DE4D35FQ33961524-57129335-1E5B-47DA-A2A1-E190F89ECA3EQ33971078-4A2FB31A-CBAF-4B75-8043-DAD254ADE228Q34182061-DAE8DD1B-EB54-40C8-B355-DEC7BA99E04DQ34186198-CDAC0424-E65F-45CC-BDF9-716CD391048FQ34409465-1A10A027-487E-46AF-A0E2-7696CF9AAAA8Q34541736-8578C46A-CB67-43FE-9558-9C43F589E49FQ34547632-C230827A-CCB6-46C3-B4A9-9F6E0F015C2BQ34558531-33447FF7-8198-449D-A246-DD3133D27226Q34611908-BDBF88A9-11BC-4EC4-8CA1-D89FC6510C98Q36024152-C2D51A0A-654D-4CAF-ABA9-ED9D53CB8F21Q36309632-06B7B3B9-5796-4A62-8D6D-7A4F5A69BC69Q36561919-7E6638C0-75B1-40B0-BE6C-2C52F7898C0DQ36590931-46927144-D798-47C5-A4C6-05D46551D3B6Q37180415-D70FC1E7-FFC9-4205-8421-9202A2513325Q37620193-EA738224-6B02-4F6F-A3F6-86521325F6A6Q37957129-FE3F1C2F-18C8-43D7-8E4C-0EAE8781170FQ38076740-DA2CDF64-C05B-4F6A-AB7C-65F256F2F91FQ38091652-E218278A-BD53-4F3E-84E9-EB85B929C15FQ38749921-CE7B12EA-51E4-402B-A2A1-BA9BA4663E53Q38840677-BADCD125-39DE-4B45-A80D-F5039D4B9C8FQ38990303-B7FCDAE5-A061-4562-AC13-5A2D6562773CQ40466387-6D6BBF4E-9E05-4EB3-8F22-30D6E70CDC98Q43805657-2AE4AB55-3013-4FE5-9227-7BEAD1073FB7Q44339785-DF33B169-7E3B-424B-9433-FFEAC17156A2Q44378161-EC06FFBD-B0FD-4F4C-BFCE-D85CBD259313Q46391214-56DE23A5-E249-4508-A250-6AABCDFBC0A2Q46690494-9B596F78-BC93-44BC-AB8B-076A9520B404Q47699933-8FA0870F-A4AC-4867-8310-D6279FD1A42DQ57543937-AB3EA15D-F0A9-48C3-A607-9CFBB4510E15Q57544295-C42352A2-57C8-48A8-8519-CDBCE35732DC
P2860
Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Safety and efficacy of vigabat ...... opean Monotherapy Study Group.
@ast
Safety and efficacy of vigabat ...... opean Monotherapy Study Group.
@en
Safety and efficacy of vigabat ...... opean Monotherapy Study Group.
@nl
type
label
Safety and efficacy of vigabat ...... opean Monotherapy Study Group.
@ast
Safety and efficacy of vigabat ...... opean Monotherapy Study Group.
@en
Safety and efficacy of vigabat ...... opean Monotherapy Study Group.
@nl
prefLabel
Safety and efficacy of vigabat ...... opean Monotherapy Study Group.
@ast
Safety and efficacy of vigabat ...... opean Monotherapy Study Group.
@en
Safety and efficacy of vigabat ...... opean Monotherapy Study Group.
@nl
P1433
P1476
Safety and efficacy of vigabat ...... opean Monotherapy Study Group.
@en
P2093
D Chadwick
P356
10.1016/S0140-6736(98)10531-7
P407
P577
1999-07-01T00:00:00Z